Benzinga | Nov 5, 2021 09:22AM EDT

Fate Therapeutics Q3 EPS $(0.45) Beats $(0.58) Estimate, Sales $14.22M Beat $7.89M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.58) by 22.41 percent. This is a 33.82 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $14.22 million which beat the analyst consensus estimate of $7.89 million by 80.29 percent. This is a 88.21 percent increase over sales of $7.56 million the same period last year.